MU Department of Medicine 2011-2013 Annual Report Feb. 2014

56 Annual Report University of Missouri- Columbia controlled, Parallel-group Study to Subjects with Type 2 Diabetes Mellitus Determine the Effects of AMG 145 Vincent DeMarco, PhD Not Achieving Adequate Glycemic Treatment on Atherosclerotic Disease Co- Principal Investigator Control on High-Dose U-100 Insulin Durden as Measured by Intervascular Impact of direct renin inhibition and Therapy with and without Oral Agents. Ultrasound in Subject Undergoing AT1R blockade on cardiovascular and Eli Lilly and Co., $69,231, 04/01/2013 Coronary Catheterization, GLAGOV, renal abnormalities associated with to 03/31/2014 $151,515, 07/01/2013 to 06/30/2014 insulin resistance in Ren2 rats: a combitorial strategy that targets the Endocrinology Shawn Bender, PhD Principal Investigator Vascular mineralocorticoid receptors and metabolic syndrome-associated coronary microvascular gene expression, Pilot Study Award, MU Internal Medicine Research Council, $12,500, 01/01/2012 to 01/01/2013 Principal Investigator Mechanisms of mineralocorticoid receptor-mediated vascular insulin resistance, Pilot Study Award, Missouri Foundation for Medical Research, $13,030, 01/01/2011 to 01/01/2013 Co-Investigator Ang II and overnutrition and insulin resistance in cardiovascular tissue, NIH/NHLBI, $743,062, 04/11/2011 to 03/31/2013 Co-Principal Investigator Impact of Saxagliptin Therapy on Angiotensin II-dependent Saltsensative Hypertension, Bristol Myers Squibb, $268,096. 03/01/2013 to 02/28/2014 Stephen Brietzke, MD Principal Inves tigator TAKEDA 491: A Randomized, DoubleBlind Phase 3b Proof of concept study to evaluate the efficacy and safety of TAK-491 compared to placebo when used in combination with metformin in subjects with hypertension and type 2 diabetes, Takeda Pharmaceuticals USA, Inc, $44,652, 09/01/2012 to 08/31/2013 Principal Investigator ALECARDIO, Hoffmann La Roche Inc., $5,500, 09/07/11 to 10/22/2013 Principal Investigator cardiometabolic syndrome, Novartis Effect of DPP-4 inhibitors on blood Pharmaceutical Corporation, $754,964, pressure and micro-albuminuria in 02/01/2010 to 04/30/2012 Type 2 diabetes, Pilot Study Award, MU Internal Medicine Research Council, Co-Principal Investigator $14,000, 05/01/2013 to 04/30/2014 Ang II and Overnutrition and Insulin Resistance in Cardiovascular Tissue, Michael Gardner, MD NIH/NHLBI, $743,062, 04/11/2011 to Co-Principal Investigator 03/31/2013 DEFEND-1: Durable-response therapy evaluation for early- or new-onset Principal Investigator type 1 diabetes, Tolerx Inc., $110,852, Comparison of Azilsartan Meoximil 11/19/2008 to 03/31/2012 and Olemsartan on Aldosterone breakthrough in hypertensive rats Principal Investigator during chronic Ang II infusion, Takeda MACROGEN-06, Macrogenics, Inc., Pharmaceuticals USA Inc., $274,149, $134,656, 11/19/2008 to 03/312012 02/01/2011 to 10/31/2012 Principal Investigator Principal Investigator DEFEND-2: Durable-response therapy Impact of Linagliptin Therapy on evaluation for early- or new-onset Cardiac and Renal function in rodent type 1 diabetes, Tolerx, Inc., $51,919, models of the metabolic syndrome, 08/12/2010 to 08/31/2012 Boehringer Ingelheim Pharmaceuticals Inc., $388,937, 02/01/2011 to Principal Investigator 07/31/2013 MACROGEN-03, Macrogenics, Inc., $82,727, 04/15/2010 to 09/30/2012 David Gardner, MD Principal Investigator Principal Investigator DEFEND-1: Durable-response therapy BIPI 1245.25: A phase III, multicenter, evaluation for early- or new-onset international, randomized, parallel type 1 diabetes, Tolerx Inc., $110,852, group, double blind cardiovascular 11/19/2008 to 03/31/2012 safety study of BI 10773 compared to usual care in type 2 diabetes mellitus Principal Investigator patients, Boehringer Ingelheim ORIGIN, Aventis Pharmaceuticals, Pharmaceuticals, Inc., $69,232, $400,000, 04/15/2004 to 05/31/2014 06/28/2012 to 02/29/2016 Principal Investigator Principal Investigator The global hypopituitary control and BMS-PEDS: A multicenter, randomized, complications study, Eli Lilly and double-blind, placebo controlled Company, $6,668, 07/15/2004 to study to evaluate the efficacy and 05/31/2004 safety of Saxagliptin in combination with Metformin IR or Metformin XR Mariana Garcia-Touza, MD in pediatric patients with type 2 Principal Investigator diabetes who have inadequate, Parexel LILLY IBHC: Two Treatment Approaches Intl. Corp., $36,468, 05/01/2012 to for Human Regular U-500 Insulin 04/30/2017 (Thrice-Daily versus Twice-Daily) in

MU Department of Medicine 2011-2013 Annual Report Feb. 2014 | Page 56